Frontlight ResearchEarly access
TerminatedNo phase
Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)
Key facts
- Who runs it
- Hi-Q Marine Biotech International, Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 87 people enrolled
- Started
- 1 Oct 2019
- Ended
- 31 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Oligo Fucoidan
- Placebo
- Record updated
- 13 January 2025
- Why it stopped
- After interim analysis, we planned to recruit 100 participants. However, due to COVID-19 challenges, statistician advised each group needs at least 30 samples (Gay, 1992). The sponsor and team decided to terminate the trial early for valid data.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 32 criteriaShow less
Who can take part
- Age > 18 years
- ECOG PS 0-2
- Histologically or cytologically documented unresectable HCC
- Measurable disease by RECIST criteria
- HCC without well control
- Child-Pugh A-B
- Albumin ≥ 2.8 g/dl
- Serum total bilirubin ≤ 3 mg/dl
- INR ≤ 2.3 or PT ≤ 6 seconds above control
- WBC ≥ 2,500/µl
- ANC ≥ 1,000/µl
- Platelets ≥ 50,000/µl
- Hb ≥ 8.5 g/dl
- Creatinine ≤ 1.5 x ULN; AND
Who cannot take part
- Prior or concomitant systemic anti-cancer treatment for HCC, including:
- Systemic chemotherapy (TACE is allowed)
- Unable to take oral medications
- BMT or stem cell rescue < 4 months; organ transplant
- Major surgical procedure, open biopsy, or significant traumatic injury < 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 2 weeks
- Patients taking narrow therapeutic index medications will be monitored closely. These include warfarin, phenytoin, quinidine, carbamazepine, phenobarbital, cyclosporine, and digoxin
- Investigational anti-cancer agents
- Severe and/or uncontrolled medical conditions:
- History of poor compliance with anti-hypertensive agents
- Active or uncontrolled infection
- Unstable angina
- GI bleeding < 30 days
- Severe renal impairment which requires dialysis; proteinuria > grade 2
- HIV infection
- Metastatic tumors
- Uncontrolled high blood pressure
- CHF
- MI or CVA < 6 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A randomized, double-blind, controlled trial was conducted evaluating the efficacy of Oligo-Fucoidan with the molecular weight ranged from 500 to 800 Da. as a supplemental therapy in patients with advanced hepatocellular carcinoma. The previous study results demonstrate the advantages of Oligo-Fucoidan in improving the disease control rate in metastatic colorectal cancer. The previous study might provide insights into the development of cancer treatments, particularly in the combination of natural or herbal products with chemotarget agents.
The 2 groups in the trial
- Treatment & Oligo FucoidanTreatment being tested
4.4 g Oligo Fucoidan powder by six months, BID
Treatment: Oligo Fucoidan
- Treatment & PlaceboPlacebo, for comparison
4.4 g Placebo powder by six months, BID
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 January 2025